$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019
[Published by Global Markets Direct]

Published by Global Markets Direct: 25 Nov 2019 | 239231 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 25 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 4 and 1 molecule, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019 [Published by Global Markets Direct]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Influenza A Virus, H5N1 Subtype Infections - Overview

    Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development

    Abivax SA

    Abzyme Therapeutics LLC

    AIM ImmunoTech Inc

    Akshaya Bio Inc

    Altimmune Inc

    Aphios Corp

    AusBio Ltd

    BiondVax Pharmaceuticals Ltd

    CEL-SCI Corp

    Chicago Biosolutions Inc

    CHO Pharma Inc

    Cocrystal Pharma Inc

    Curevac AG

    Declion Pharmaceuticals Inc

    FluGen Inc

    Gamaleya Federal Research Center of Epidemiology and Microbiology

    Gamma Vaccines Pty Ltd

    Global BioLife Inc Ltd

    Greffex Inc

    i2 Pharmaceuticals Inc

    Inovio Pharmaceuticals Inc

    Johnson & Johnson

    Kineta Inc

    Medicago Inc

    Medigen Inc

    NanoViricides Inc

    New Amsterdam Sciences Inc

    OPKO Health Inc

    PeptiDream Inc

    Seqirus Ltd

    Shionogi & Co Ltd

    TechnoVax Inc

    Tria Bioscience Corp

    Vacthera BioTech GmbH

    Vaxart Inc

    Vaxine Pty Ltd

    Virion Biotherapeutics

    Virvio Inc

    Influenza A Virus, H5N1 Subtype Infections - Drug Profiles

    (oseltamivir phosphate + pimodivir hydrochloride) - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    A-06 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ABX-196 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Alferon LDO - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    APP-0205 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    APP-309 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    baloxavir marboxil - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CC-42344 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CEL-1000 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CHOS-05 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CV-7302 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    DPC-005 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GamFluVac - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Gamma-Flu - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GREFLU/VIE - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    HB-36.6 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    infectious disease vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    influenza (quadrivalent) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    influenza [strain A /Vietnam/1203/04 (H5N1)] (monovalent) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    influenza [strain A/H5N1] (split virion) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    influenza [strain A/H5N1] vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    influenza [strain A/H5N1] vaccine 2 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    KIN-1148 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    LB-2 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    M-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MD-2009 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MDG-8972 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NAS-911 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Nasovax - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NVINF-1 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NVINF-2 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    PD-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Peptides for Influenza Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    pimodivir hydrochloride - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    REDEE FLU - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    rintatolimod - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule for Influenza Virus Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit PB2 for Influenza A Virus Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TVX-003 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VGX-3400X - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VH-244 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VTH-201 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Influenza A Virus, H5N1 Subtype Infections - Dormant Projects

    Influenza A Virus, H5N1 Subtype Infections - Discontinued Products

    Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones

    Featured News & Press Releases

    Apr 12, 2019: Vaxart to present at the 29th European Congress of Clinical Microbiology & Infectious Diseases

    Apr 11, 2019: Altimmune to present NasoVAX Phase 2 data at the World Vaccine Congress in Washington, D.C.

    Mar 06, 2019: FDA accepts Genentech’s supplemental new drug application for XOFLUZA (baloxavir marboxil) for the treatment of influenza in people at high risk of complications

    Sep 17, 2018: Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO

    Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine

    Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases

    Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases

    Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant

    Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress

    Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak

    Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.

    Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine

    Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting

    Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company’s Universal Flu Vaccine

    Jan 21, 2014: BiondVax’s universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

239231 | GMDHC11543IDB

Number of Pages

180

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Global Influenza Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Influenza B Infections Global Clinical Trials Review, H1, 2016
Influenza B Infections Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial rep...
20 Jan 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Pandemic Influenza Global Clinical Trials Review, H1, 2016
Pandemic Influenza Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report,...
20 Jan 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Influenza A Infections Global Clinical Trials Review, H1, 2016
Influenza A Infections Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial rep...
20 Jan 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical...
20 Jan 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Swine Influenza Global Clinical Trials Review, H1, 2016
Swine Influenza Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “S...
20 Jan 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Seasonal Influenza Global Clinical Trials Review, H2, 2015
Seasonal Influenza Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report,...
30 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Influenza A Infections Global Clinical Trials Review, H2, 2015
Influenza A Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial rep...
30 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Pandemic Influenza Global Clinical Trials Review, H2, 2015
Pandemic Influenza Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report,...
30 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Influenza B Infections Global Clinical Trials Review, H2, 2015
Influenza B Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial rep...
30 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...